|5.||Neoplasm Metastasis (Metastasis)
|1.||Langendijk, Johannes A: 45 articles (11/2015 - 09/2004)|
|2.||Ferris, Robert L: 39 articles (10/2015 - 01/2004)|
|3.||Grandis, Jennifer R: 36 articles (01/2015 - 09/2005)|
|4.||Garden, Adam S: 35 articles (09/2015 - 02/2004)|
|5.||Eisbruch, Avraham: 33 articles (12/2015 - 05/2002)|
|6.||Shin, Dong M: 33 articles (11/2015 - 01/2004)|
|7.||Leemans, C René: 32 articles (01/2016 - 09/2004)|
|8.||Argiris, Athanassios: 32 articles (06/2015 - 05/2002)|
|9.||Vokes, Everett E: 31 articles (09/2014 - 01/2003)|
|10.||Overgaard, Jens: 30 articles (12/2015 - 01/2003)|
|1.||Cisplatin (Platino)FDA LinkGeneric
01/01/2012 - "The objective of this study was to evaluate the feasibility, toxicity and efficacy of postoperative radiochemotherapy with weekly cisplatin in locoregionally advanced or high risk head and neck cancer in a single institutional setting. "
03/21/2012 - "Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio."
06/01/2001 - "Cisplatin is a widely used chemotherapeutic agent in head and neck cancer, and is particularly effective in combination with radiation therapy. "
07/01/1997 - "Accelerated twice-daily radiation with concurrent cisplatin is effective in locally advanced head and neck cancer and can be safely given with manageable toxicity."
02/01/1986 - "It is therefore concluded that cisplatin is markedly useful for the treatment of head and neck cancer."
|2.||Fluorouracil (Carac)FDA LinkGeneric
02/01/1991 - "The radiosensitization properties of 5-FU are well documented, and clinical trials have suggested improved local control and survival in head and neck cancer. "
09/01/2005 - "Although we could not show a benefit in survival with the CDDP + 5-FU protocol, this trial supports literature data and confirms that this regimen may be proposed as a first-line therapy in advanced cancer of the head and neck."
12/01/2004 - "Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity."
01/01/1999 - "Forty-two patients with advanced head and neck cancer entered this phase II trial of long-term continuous 5-fluorouracil (5-FU) infusion at a dose of 300 mg/m2/day for a maximum of 16 weeks. "
11/01/1994 - "Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results."
|3.||cetuximab (Erbitux)FDA Link
01/01/2006 - "Indeed, one of the more striking clinical results in this field has been recently achieved by combining an EGFR inhibitor (cetuximab) with radiation in the treatment of advanced head and neck cancer patients. "
09/01/2004 - "Preclinical data provide proof-of-principle that local tumour control may be improved by combining irradiation with C225 mAb. In a randomised phase III clinical trial, simultaneous irradiation and treatment with the EGFR antibody Cetuximab (Erbitux; C225) in head and neck cancer patients resulted in significantly improved locoregional tumour control and survival compared to curative irradiation alone. "
06/01/2015 - "The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. "
10/01/2009 - "The Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer (EXTREME) Phase III trial compared platin-5-fluorouracil alone versus combined with cetuximab as first-line treatment in recurrent or metastatic SCCHN. "
03/01/2009 - "We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer) trial. "
|4.||Paclitaxel (Taxol)FDA LinkGeneric
06/01/2005 - "Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian, lung, and head and neck cancer. "
10/01/2000 - "These data suggest that paclitaxel may be effective for treating CDDP resistant head and neck cancer."
09/01/2011 - "To evaluate the efficacy and safety of weekly paclitaxel in patients with recurrent or metastatic head and neck cancer (HNC) by combined analysis of early and late phase II trials. "
05/01/2005 - "Aim of the present study was to test, activity and toxicity of a rapidly alternating chemoradiation (paclitaxel based) in 31 patients with unresectable, locally advanced or recurrent after surgery, head and neck cancer. "
06/01/1995 - "We report a phase II trial of paclitaxel in patients with head and neck cancer, not only to evaluate its clinical effects, but also to study its effect on cytokine release. "
|5.||docetaxel (Taxotere)FDA Link
03/01/1996 - "Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer."
03/01/2010 - "The result of this preclinical in vivo study is promising and supports further clinical testing to evaluate efficacy of combined intratumoral docetaxel and Ad-p53 in treatment of head and neck cancer."
11/01/2005 - "A pilot study was conducted to evaluate the safety and efficacy of weekly docetaxel(DOC) treatment for head and neck cancer as compared with those of 3-weekly DOC treatment at 60 mg/m(2). "
11/01/2005 - "To examine the feasibility and efficacy of concurrent weekly docetaxel and radiation therapy as a definitive treatment for head and neck cancer (HNC). "
04/01/2007 - "Postoperative radiation therapy with weekly docetaxel 20 or 25 mg/m(2)/week for high-risk postoperative head and neck cancer caused intolerable mucosal toxicity, prompting early study termination. "
|6.||Carboplatin (JM8)FDA LinkGeneric
01/01/1993 - "Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 days/week to a total dose of 64-70 Gy over 7-8 weeks) in a Phase I/II study. "
01/01/1993 - "Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer."
06/01/1992 - "Response rates and toxicity we observed during this study clearly show that the combination of carboplatin and radiation therapy is effective and suitable for the treatment of patients with stage IV head and neck cancer."
07/01/1988 - "To evaluate the clinical efficacy and safety of carboplatin for head and neck cancer, a phase II study was conducted in 21 institutions. "
07/01/1988 - "[Phase II study of carboplatin in head and neck cancer]."
|7.||Amifostine (Ethyol)FDA LinkGeneric
02/01/2006 - "Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy."
12/01/2004 - "A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing."
01/01/2010 - "The aim of the present study was to explore the effects of amifostine on the radiation-induced apoptosis of peripheral blood lymphocytes from patients suffering head and neck cancer. "
02/01/2007 - "A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer."
03/01/2006 - "This randomized, double-blinded, placebo-controlled, phase III study evaluated the efficacy and safety of i.v. amifostine during radiochemotherapy for head-and-neck cancer. "
01/01/2004 - "It has to be stressed that PDT is still less effective in the treatment of more advanced cases of head and neck cancer. "
03/01/2009 - "Selected patients with advanced cancer of the head and neck, who have exhausted other treatment options, can also achieve improvement in quality of life with PDT. "
11/01/1995 - "We feel there is now sufficient evident of the efficacy of this treatment to warrant a multicentre prospective study into the treatment of early head and neck cancer with PDT."
01/01/2014 - "Therefore, this study may lead to a potential drug-PDT combination that may be a useful treatment modality for human head and neck cancer. "
04/01/2007 - "To investigate the effect of sublethal PDT on the invasiveness of head and neck cancer cells and to elucidate the possible mechanisms, we initiated this study. "
06/01/1983 - "Innovative studies of the high-dose, infusion platinum therapy may clarify the efficacy of the program in patients with advanced head and neck cancer."
11/01/2002 - "We are presently developing a phase II trial of this regimen for patients with platinum-resistant head and neck cancer."
07/01/1987 - "Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study."
06/01/1983 - "Intratumor platinum concentrations derived from this study provide guidance for selection of the appropriate drug concentrations for in vitro chemosensitivity testing of head and neck cancer in humans."
04/01/2015 - "Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. "
|10.||Epidermal Growth Factor Receptor (EGF Receptor)IBA
04/15/2015 - "MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells."
08/01/2011 - "Epidermal growth factor receptor (EGFR) overexpression is correlated with decreased survival in head and neck cancer (HNC) where the addition of EGFR inhibition to standard chemoradiation approaches has improved treatment responses. "
01/01/2007 - "Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer."
01/01/2015 - "Although the epidermal growth factor receptor (EGFR) is an established target in head-and-neck cancer (HNC), resistance to EGFR-targeted therapy mediated by various mechanisms has been reported. "
01/01/2015 - "We successfully use this system to create a pINDUCER-EmGFP-miRNA27a expression vector and generate a stable head and neck cancer cell line (UM-SCC-22A) that inducibly expresses miRNA-27a, resulting in targeted epidermal growth factor receptor down regulation. "
|1.||Drug Therapy (Chemotherapy)
10/01/2010 - "Although highly debated in the 1980s, randomized clinical trials have provided undeniable evidence that systemic chemotherapy, as part of a multimodality treatment collaboration, is effective in improving survival, organ preservation and local-regional control in locally advanced head and neck cancer (HNC). "
04/15/2015 - "Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis?"
06/01/2005 - "Neoadjuvant chemotherapy has been reported to be extremely active in head and neck cancer but has failed to give a statistically significant improvement in survival. "
01/01/2009 - "The addition of chemotherapy to radiation in the treatment of advanced-staged head and neck cancer has improved local-regional control and increased complete clinical and pathologic response rates in the neck. "
03/01/2008 - "Although meta-analysis showed that survival improved with concurrent chemoradiation in locally advanced head and neck cancer, neoadjuvant chemotherapy is still unique, because it renders curative surgery feasible for marginally resectable head and neck cancer patients. "
09/01/2011 - "Radiotherapy is one of the most effective treatments for head and neck cancer. "
09/01/2011 - "Radiotherapy is one of the most effective treatments for head and neck cancer. "
11/01/2007 - "Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. "
04/01/1995 - "The best treatment for cancer of the head and neck remains surgery followed by radiotherapy. "
01/01/2011 - "With the advances in modern radiotherapy (RT), many patients with head and neck cancer (HNC) can be effectively cured, and their health-related quality of life (HR-QoL) has become an important issue. "
|3.||Neck Dissection (Radical Neck Dissection)
01/01/2015 - "Neck dissection is the most definitive and effective treatment for head and neck cancer. "
02/01/2010 - "The question of efficacy of "planned" neck dissection following complete response to chemoradiation of head and neck cancer is discussed. "
02/01/1975 - "It is suggested that the last major improvement in the surgical treatment of head and neck cancer was Crile's description of radical neck dissection in 1906, and that modifications of this procedure, including extended surgery, have made little or no difference to survival rates. "
11/01/2008 - "Selective neck dissection as a part of an elective or therapeutic treatment of the neck is a common practice during the surgical treatment of patients with head and neck cancer. "
02/01/2014 - "[Surgery for head and neck cancer: is harmonic scalpel safe and effective for neck dissection?]."
|4.||Combination Drug Therapy (Combination Chemotherapy)
08/01/1985 - "Despite good results of polychemotherapy in head and neck cancer, monochemotherapy retains a valuable role in managing patients with advanced disease. "
11/01/2014 - "[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy]."
12/01/2009 - "Combination chemotherapy for head and neck cancer: the addition of Bcl-2 inhibitors."
06/01/2008 - "To investigate the prognostic value of the pre-treatment haemoglobin level in patients with advanced squamous cell head and neck cancer treated with induction polychemotherapy. "
06/01/2008 - "Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients."
|5.||Heterologous Transplantation (Xenotransplantation)
07/01/2007 - "Finally, we show that the AC inhibitor LCL 204 can sensitize HNSCC cell lines to Fas-induced apoptosis both in vitro and in a xenograft model in vivo, suggesting that the combination of FasL gene therapy and LCL 204 may become a new treatment option for advanced-stage head and neck cancer."
01/01/1984 - "The potential of the nude mouse xenograft model for the study of head and neck cancer."
04/01/2015 - "We investigated the efficacy and pharmacokinetic/pharmacodynamic properties of HER3 signal inhibition by RG7116 in a murine xenograft model of human head and neck cancer. "
10/01/2014 - "Gene expression changes during repopulation in a head and neck cancer xenograft."
01/01/2014 - "Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts."